Differences in Early-Onset Bowel Cancer Among Younger Patients
Research indicates that bowel cancer diagnosed before age 50 exhibits unique characteristics, differentiating it from cases diagnosed later. Key findings in a study published in The Medical Journal of Australia show variations in tumor traits, genetics, and survival rates among younger patients.
Bowel Cancer Characterization
Researchers analyzed data from 1,691 Australians with liver-metastasized bowel cancer, comparing patients aged 50 or younger with those over 50. This investigation uncovered distinct features of early-onset bowel cancer, which may impact treatment approaches.
Professor Savio George Barreto from Flinders University spearheaded the study. He emphasized the urgent need to understand factors driving increased bowel cancer rates in younger adults in Australia. This country has notably high early-onset bowel cancer rates.
We hypothesize that if exposures/stressors overwhelm the body’s protective systems at critical life periods, it could trigger epigenetic modifications.— Professor Barreto
Factors like smoking, alcohol use, obesity, and illicit drug use are posited as contributors to these modifications.
Biological and Genetic Differences
The study highlights disparities in cancer presentation and survival between younger and older patients. Young patients are more likely to be women, have tumors on the left side of the bowel, and possess specific genetic mutations. These differences confer a survival advantage; younger patients typically live longer after the cancer has spread to the liver compared to older patients.
The biological profile of early-onset bowel cancer appears distinct from late-onset cases. Barreto notes this reinforces theories held for some time by researchers. Genetic testing emerges as crucial, with BRAF and KRAS mutations linked to poorer outcomes regardless of age. Tumor genetic characteristics are important for personalized treatment approaches.
The new finding in this study is the value of NRAS mutations, too, to guide treatment strategies.— Professor Barreto
These insights push for considering tumor biology over merely age in medical decision-making.
Treatment Strategies and Outcomes
Research further delves into treatment strategies across different age groups. Surgery followed by drug treatment shows better outcomes for patients. Particularly, younger patients benefit from upfront curative surgery when feasible, contrasting with older patients possibly benefitting from initial chemotherapy, especially those with metastatic right-sided cancers.
While promising, these findings derive from real-world data rather than controlled trials, meaning other factors may influence results. Continued research could clarify how to address rising bowel cancer rates among younger adults.
Supporting Younger Survivors
Addressing the needs of younger survivors remains a priority, as their requirements often differ from older patients. Barreto underscores the potential of identifying biomarkers for early risk detection.
Can we identify epigenetic blood biomarkers of people at risk? This will offer the ability to identify individuals at risk early on with targeted screening in the future.— Professor Barreto
Ultimately, these findings advocate treating early-onset bowel cancer as a distinct disease, with potential improvements in personalized treatment and patient care shaping future strategies.
The study concludes with strengthening the notion that early-onset bowel cancer diverges significantly from cases appearing later in life, emphasizing personalized treatment approaches.
Reference: Savio G. Barreto et al. Early-Onset Colorectal Cancer With Liver-Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real-World Clinical and Molecular Data From an Australian National Database (2009–2024) to Guide Treatment Planning. The Medical Journal of Australia. DOI: 10.5694/mja2.70266